Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America

University of Mississippi Medical Center, Jackson, USA.
Clinical Infectious Diseases (Impact Factor: 8.89). 07/2008; 46(12):1801-12. DOI: 10.1086/588300
Source: PubMed


Evidence-based guidelines for the management of patients with blastomycosis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous management guidelines published in the April 2000 issue of Clinical Infectious Diseases. The guidelines are intended for use by health care providers who care for patients who have blastomycosis. Since 2000, several new antifungal agents have become available, and blastomycosis has been noted more frequently among immunosuppressed patients. New information, based on publications between 2000 and 2006, is incorporated in this guideline document, and recommendations for treating children with blastomycosis have been noted.

Download full-text


Available from: Laurie Proia,
  • Source
    • "Eine paradigmatische Situation wäre beispielsweise, wenn Gremien wenig Vertrauen in den Vorteil einer Intervention bezogen auf eine Entscheidung über Leben und Tod haben. Denken Sie an Patienten, die an einer lebensbedrohlichen disseminierten Blastomykose leiden [27] "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the GRADE approach, the strength of a recommendation reflects the extent to which we can be confident that the composite desirable effects of a management strategy outweigh the composite undesirable effects. This article addresses GRADE's approach to determining the direction and strength of a recommendation. The GRADE describes the balance of desirable and undesirable outcomes of interest among alternative management strategies depending on four domains, namely estimates of effect for desirable and undesirable outcomes of interest, confidence in the estimates of effect, estimates of values and preferences, and resource use. Ultimately, guideline panels must use judgment in integrating these factors to make a strong or weak recommendation for or against an intervention.
    Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen 12/2014; 108(7). DOI:10.1016/j.zefq.2014.08.004
  • Source
    • "Blastomyces dermatitidis and the newly described Blastomyces gilchristi [1], dimorphic fungi, are capable of causing blastomycosis infection among humans, dogs, and other mammals. The primary route of infection is through inhalation of fungal conidia [2]. Severity of infection in humans can vary greatly with the most severe cases resulting in death. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We used the State Inpatient Databases from the United States Agency for Healthcare Research and Quality to provide state-specific age-adjusted blastomycosis-associated hospitalization incidence throughout the entire United States. Among the 46 states studied, states within the Mississippi and Ohio River valleys had the highest age-adjusted hospitalization incidence. Specifically, Wisconsin had the highest age-adjusted hospitalization incidence (2.9 hospitalizations per 100,000 person-years). Trends were studied in the five highest hospitalization incidence states. From 2000 to 2011, blastomycosis-associated hospitalizations increased significantly in Illinois and Kentucky with an average annual increase of 4.4% and 8.4%, respectively. Trends varied significantly by state. Overall, 64% of blastomycosis-associated hospitalizations were among men and the median age at hospitalization was 53 years. This analysis provides a complete epidemiologic description of blastomycosis-associated hospitalizations throughout the endemic area in the United States.
    PLoS ONE 08/2014; 9(8):e105466. DOI:10.1371/journal.pone.0105466 · 3.23 Impact Factor
  • Source
    • "Amphotericin B is no longer recommended as sole therapy due to toxicity with itraconazole having fewer side effects and an efficacy over 90% in non–life-threatening blastomycosis (Bradsher, 1996; Chapman et al., 1997; Chapman et al., 2008; Dismukes et al., 1992). Voriconazole and posaconazole have in vitro activity against B. dermatitidis but are not well studied in the treatment of blastomycosis (Chapman et al., 2008; Li et al., 2000; Sugar and Liu, 1996). Voriconazole has been used to treat blastomycosis in the setting of itraconazole intolerance or sub-therapeutic drug levels and has been successful in the treatment of central nervous system blastomycosis (Borgia et al., 2006; Freifeld et al., 2009; Freifeld et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Blastomycosis commonly occurs following inhalation of Blastomyces dermatitidis conidia causing a pulmonary infection and can disseminate to extrapulmonary sites. Osseous involvement primarily results from hematogenous spread but in rare cases direct inoculation can occur. We describe a case of osseous blastomycosis without pulmonary or disseminated disease successfully treated with posaconazole.
    Diagnostic microbiology and infectious disease 06/2014; 79(2). DOI:10.1016/j.diagmicrobio.2014.02.021 · 2.46 Impact Factor
Show more